ARTICLE | Company News

Concert rises after selling CF programs to Vertex

March 6, 2017 9:57 PM UTC

Concert Pharmaceuticals Inc. (NASDAQ:CNCE) jumped $5.99 (62%) to $15.64 on Monday after it said Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) will acquire all of its cystic fibrosis programs, including CTP-656, a deuterated version of Vertex's Kalydeco ivacaftor. Concert is to receive $160 million in upfront cash and is eligible for $90 million in regulatory milestones.

Concert expects top-line data in 4Q17 from a Phase II trial comparing CTP-656 with Kalydeco and placebo in CF patients with CF transmembrane conductance regulator (CFTR) gating mutations. The deal also includes "research and preclinical" CF programs, Concert said...

Access The Full Article